Evaluation of the efficacy and safety of domestic irbesartan in treatment of primary hypertension

张云,李一石,蒋文,王莉,边文,华路,龚培,刘国树,柯元南,郭静宣,孙宁玲
DOI: https://doi.org/10.3321/j.issn:1003-3734.2001.06.016
2001-01-01
Abstract:Objective:To evaluate the clinical efficacy and safety of domestic irbesartan (Irb) in treatment of primary hypertension.Methods:236 patients with SeDBP (seated diastolic blood pressure) of 12.67~15.33 kPa were randomly divided to once daily 150 mg of Irb(n=119) or once daily 10 mg of benazepril(Ben,n=117) for 4 weeks,after 1-week wash out and 2-week placebo run-in period.49 patients took part in an open clinical trial of 24 weeks.They were treated initially with once daily 150 mg of Irb,after 4 weeks the Irb dose was incresed to 300 mg·d -1 for patients with SeDBP≥12.00 kPa until to the end of the trial.The BP,heart rate,tolerability were measured and recored at weeks 4,8,12,16,20 and 24.Results:The effective rate for Irb and Ben were 79.0% and 77.8%(P0.05) respectively after 4 weeks treatment,SeDBP was significantly decreased by (2.00±1.07)kPa at the end of 24 weeks' open clinical trial(P0.05),the incidence of ADRs and cough for Irb in 24 weeks trial were 14.3% and 1.8%.Conclusion:The domestic Irb in doses of 150~300 mg·d -1 are a safe,effective and torlerable agent for treatment of primary hypertension.
What problem does this paper attempt to address?